United States Colon Screening Market Report by Type, End Use, States and Company Analysis, 2026-2034

United States Colon Screening Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Colon Screening Market is expected to reach US$ 6.77 Billion by 2034 from US$ 5.11 Billion in 2025, with a CAGR of 3.18% from 2026 to 2034. The United States Colon Screening Market is expanding through wider awareness of colorectal cancer prevention, increasing availability of non-invasive screening options, improved access to testing, and growing adoption of stool- and blood-based technologies that can complement established colonoscopy-based screening pathways.

United States Colon Screening Industry Landscape

Colon screening refers to tests and procedures used to detect colorectal cancer or precancerous abnormalities before symptoms become apparent. Screening approaches include stool-based tests, blood-based tests and visual examinations such as colonoscopy and CT colonography. Stool tests can identify hidden blood or molecular markers associated with colorectal abnormalities, while blood-based technologies analyze circulating biological signals. Colonoscopy allows physicians to directly examine the colon and remove certain polyps during the procedure. The choice of screening method depends on individual risk, medical history, age, physician recommendations and applicable screening guidance. Positive results from non-invasive tests generally require appropriate diagnostic follow-up, including colonoscopy.

Growing interest in convenient and less invasive screening methods is reshaping the U.S. colon screening landscape. Traditional colonoscopy remains an important screening and diagnostic procedure, but stool-based and blood-based technologies are creating additional pathways for individuals who may hesitate to undergo an invasive examination. Improvements in molecular testing are enabling screening platforms to examine biological signals associated with colorectal cancer and precancerous disease. Healthcare providers are also incorporating screening into routine primary-care interactions, making testing easier to discuss and prescribe. Increased awareness, expanding insurance coverage and the development of new screening technologies are collectively supporting broader participation and diversification within the U.S. colon screening market.

Recent Breakthroughs Shaping the United States Colon Screening Industry

• In February 2026, Guardant Health launched a community colorectal cancer screening grant program supporting nonprofit, public-health and patient-advocacy organizations. Selected organizations could receive Shield tests for community screening events and educational activities. Rather than representing a new diagnostic product, this development demonstrates a market shift toward community-based screening programs and outreach designed to connect non-invasive testing with populations that may have limited participation in conventional screening pathways.

Major Growth Drivers Shaping the Future of United States Colon Screening Sector

1. At-Home RNA Testing Makes Colorectal Screening More Convenient

The growing availability of at-home molecular screening is creating new opportunities for the United States Colon Screening Market. Stool-based tests allow eligible individuals to collect samples at home and complete initial screening without visiting a facility for an invasive procedure. Advances in molecular analysis are further enhancing this approach by enabling tests to examine biological signals beyond conventional blood detection.

In June 2026, Labcorp announced nationwide availability of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test. The test analyzes RNA biomarkers and hemoglobin from stool samples and provides another non-invasive option for eligible screening populations. Its broader availability demonstrates how diagnostic companies are improving the convenience and accessibility of stool-based screening. Continued development of simplified collection procedures, molecular biomarkers and laboratory automation can encourage healthcare providers to incorporate at-home testing into preventive-care pathways while giving patients additional screening options alongside established colonoscopy services.

2. Consumer-Accessible Testing Is Creating New Screening Pathways

Greater accessibility to colorectal screening is encouraging the development of testing models that can reach individuals outside traditional physician-office pathways. Direct-to-consumer services can make it easier for eligible adults to learn about screening and initiate testing, while healthcare professionals remain important for interpreting results and arranging appropriate follow-up.

In May 2025, New Day Diagnostics announced the launch of ColoHealth, a laboratory-developed blood test offered through a direct-to-consumer model in most U.S. states. The company positioned the test as an additional option for people who may not complete conventional colonoscopy or stool-based screening. This development illustrates how consumer-oriented healthcare models are becoming part of the broader colorectal screening ecosystem. Digital ordering, laboratory networks and remote communication can further simplify access. As providers and diagnostic companies explore patient-centered delivery models, consumer accessibility may become an increasingly relevant factor in expanding participation and connecting more individuals with appropriate colorectal cancer screening pathways.

3. Laboratory Automation Is Strengthening Established Stool-Screening Platforms

Continuous improvements in laboratory processing are supporting the development of established stool-based colorectal screening platforms. Beyond introducing new tests, manufacturers are refining reagents, analytical procedures and laboratory instruments to improve how screening samples are processed at scale.

In June 2026, the U.S. FDA approved a supplement for Cologuard involving reagent scale-up and an improved in-process quality-control method. The FDA also authorized a new laboratory instrument associated with the Cologuard Plus workflow. These developments demonstrate how established screening platforms can evolve through manufacturing and laboratory-process improvements. Such upgrades can support consistent testing as healthcare organizations and laboratories manage screening programs across broader populations. Improvements in automation may also help laboratories streamline sample processing and maintain quality-control procedures. Continued investment in laboratory infrastructure, analytical equipment and standardized workflows can therefore contribute to the expansion of stool-based screening while supporting the reliability and scalability of existing colorectal cancer screening services.

Critical Challenges Facing the United States Colon Screening Industry

1. Follow-Up After Positive Non-Invasive Results

Non-invasive screening methods can make testing more accessible, but they do not eliminate the need for diagnostic follow-up when an abnormal result occurs. A positive stool- or blood-based screening result generally requires colonoscopy to determine whether cancer, precancerous lesions or another abnormality is present. Consequently, the effectiveness of a screening pathway depends not only on initial test participation but also on timely completion of recommended follow-up. Healthcare systems need processes for communicating results, arranging specialist appointments and coordinating diagnostic procedures. Delays between screening and follow-up can complicate patient management. Building integrated referral and navigation systems therefore remains an important challenge as alternative screening technologies become more widely used.

2. Patient Participation and Screening-Method Preferences

Increasing the availability of screening options does not automatically guarantee consistent participation. Individuals may have different preferences regarding stool collection, blood draws or visual procedures, while concerns about preparation, privacy, discomfort and inconvenience can influence their choices. Healthcare professionals must explain the purpose, appropriate use and follow-up requirements of available tests so patients can make informed decisions. Screening providers also need to account for differences in risk profiles, medical histories and previous screening results. Maintaining participation requires more than introducing new technologies; it involves effective patient education, accessible healthcare pathways and appropriate clinician engagement. Balancing convenience with medically appropriate screening remains an ongoing market challenge.

California – Molecular Innovation Meets Preventive Cancer Care

California provides an important environment for the development and adoption of advanced colon screening technologies because of its extensive healthcare infrastructure, biotechnology ecosystem and concentration of research-oriented medical institutions. Providers can incorporate stool-based, blood-based and conventional visual screening approaches according to patient circumstances and applicable clinical guidance. The state's biotechnology sector also supports innovation in molecular diagnostics, creating opportunities for companies developing non-invasive screening technologies. Primary-care practices can play an important role by discussing screening options during routine healthcare visits and coordinating follow-up where required. California's combination of technology development, healthcare delivery and research activity creates opportunities for emerging screening platforms while maintaining an important role for established colonoscopy services.

Texas – Expanding Access Across a Diverse Healthcare Network

Texas has a broad network of hospitals, primary-care providers, specialty centers and community healthcare facilities that can support multiple colorectal screening pathways. Stool-based and blood-based tests can provide additional options for eligible individuals, while colonoscopy remains an important diagnostic and screening procedure. Large healthcare networks can incorporate screening reminders, laboratory testing and referral systems into established preventive-care programs. Rural and community-based healthcare settings may also create opportunities for convenient screening technologies that can be initiated without specialized procedural infrastructure. Manufacturers and healthcare providers can therefore focus on improving accessibility, patient education and follow-up coordination. Texas's diverse healthcare environment supports a broad range of screening models across primary, specialty and hospital-based care.

New York – Precision Diagnostics Strengthen the Screening Landscape

New York's concentration of academic medical centers, hospitals, specialty practices and diagnostic laboratories provides opportunities for advanced colorectal screening technologies. Healthcare providers can integrate molecular, stool-based and blood-based screening into preventive-care programs while maintaining colonoscopy services for appropriate diagnostic follow-up. Research institutions can also contribute to the evaluation of emerging technologies and screening strategies. Digital health infrastructure may help providers identify patients due for screening, communicate test results and coordinate follow-up procedures. As molecular diagnostics continue developing, New York's healthcare ecosystem can provide an environment for clinicians and diagnostic companies to evaluate new approaches. The state's market therefore combines established procedural screening with growing interest in less-invasive diagnostic technologies.

Florida – Convenience and Preventive Care Shape Screening Demand

Florida's healthcare environment includes hospitals, primary-care practices, specialty centers, laboratories and extensive outpatient services, creating opportunities for diverse colorectal screening approaches. Stool-based and blood-based tests can provide convenient options for eligible individuals, while healthcare providers can coordinate colonoscopy when diagnostic evaluation is required. Home-based collection can also make certain screening pathways easier to incorporate into routine preventive care. Healthcare organizations may use patient reminders and screening programs to encourage appropriate participation and follow-up. Diagnostic laboratories and medical providers can benefit from increasing adoption of molecular testing as new technologies enter the market. Florida's combination of outpatient healthcare, preventive services and home-oriented care models supports continued diversification of colon screening options.

United States Stool-Based Colon Screening Market – Convenient Testing Moves Screening Beyond the Clinic

The United States Stool-Based Colon Screening Market remains an important part of colorectal cancer prevention because stool testing can be completed without an invasive procedure. Available approaches include tests that detect occult blood and multi-target molecular tests that examine stool for biological signals associated with colorectal abnormalities. At-home collection can make screening more convenient and reduce the need for an initial clinical procedure. Healthcare providers can prescribe or recommend appropriate tests based on patient characteristics and screening guidance. Advances in collection kits, laboratory processing and molecular analysis are supporting continued product development. Positive findings require appropriate diagnostic evaluation, typically including colonoscopy, making coordination between non-invasive screening and follow-up services an important part of this market.

United States Hospitals & Clinics Colon Screening Market – Integrated Care Connects Screening With Diagnosis

The United States Hospitals & Clinics Colon Screening Market encompasses screening services delivered through hospitals, outpatient centers, primary-care practices, gastroenterology clinics and other healthcare facilities. These organizations can provide or coordinate stool-based testing, blood-based screening and visual procedures according to patient needs and applicable clinical recommendations. Hospitals and clinics also play a central role in follow-up after abnormal non-invasive screening results. Digital reminders, laboratory integration and referral-management systems can help healthcare organizations organize screening pathways. As new molecular and blood-based technologies become available, providers may increasingly incorporate multiple screening choices into preventive-care discussions. This creates opportunities for healthcare organizations to develop more connected screening-to-diagnosis pathways while maintaining established colonoscopy capabilities.

Market Segmentations

Type

• Stool-based
• Colonoscopy
• Others

End Use

• Hospitals & Clinics
• Clinical Laboratories
• Diagnostic Imaging Centers
• Others

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. Olympus Corporation
2. FUJIFILM Holdings Corporation
3. Medtronic
4. Ambu A/S
5. Bracco
6. Varay Laborix
7. EndoFresh (Daichuan medical)
8. Baxter (Hillrom & Welch Allyn)

Report Details: